BioLife Solutions Q2 Revenue Jumps 21% to $28.5M; Repligen Merger Announced at $31/Share
BLFS sits 90% above its 52-week low of $17.86.
Summary
BioLife Solutions reported Q2 2026 revenue of $28.5M (+21% YoY) and net income of $45.1M, boosted by a tax valuation allowance release. The company also disclosed a pending acquisition by Repligen at $31/share, valuing the company at $1.5B.
Key Events · Earnings and Guidance · BLFS
-
Q2 Revenue Up 21% to $28.5M
Revenue grew to $28.5 million in Q2 2026, up 21% from $23.4 million a year ago, driven by strong demand for biopreservation media. Six-month revenue reached $56.0 million, a 23% increase.
-
Net Income Boosted by $42.4M Tax Benefit
Net income surged to $45.1 million in Q2, primarily due to a $42.4 million release of deferred tax valuation allowance, reflecting sustained profitability. Operating income was $1.7 million.
-
Repligen Merger Announced at $31/Share
On July 21, 2026, BioLife entered into a definitive merger agreement with Repligen, which will acquire all outstanding shares for $11.25 cash and 0.1442 shares of Repligen per BioLife share, implying a $31.00 per share value and $1.5 billion enterprise value.
-
Term Loan Fully Repaid
The company repaid its remaining term loan balance and a $1.2 million balloon payment upon maturity on June 1, 2026, leaving no long-term debt on the balance sheet.
Analysis · BLFS · Industrial Applications And Services
A standout quarter for BioLife Solutions saw revenue climb 21% year-over-year to $28.5 million, fueled by its leading biopreservation media products. The bottom line got an extraordinary lift from a $42.4 million deferred tax valuation allowance release, which transformed a modest operating profit into $45.1 million in net income. Even more consequential, the company disclosed a definitive agreement to be acquired by Repligen for $31 per share in cash and stock — a deal that values BioLife at $1.5 billion and will take the company private. The merger, announced July 21, is expected to close in Q4 2026, subject to shareholder and regulatory approvals. This 10-Q offers the first detailed look at the financial health of the business ahead of that transaction.
How filings like this one have moved
In the 30 days to Sep 30, 2026, 34.9% of the 1009 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.52%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, BLFS was trading at $33.93 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $1.7B. The 52-week trading range was $17.86 to $34.34. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.